Article metrics
PDF
Other content recommended for you
- Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline
- Update on disease-modifying therapies for multiple sclerosis
- Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications
- Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring
- Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events
- Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
- Disease modifying therapies for relapsing multiple sclerosis
- Disease-modifying therapies for multiple sclerosis
- JC viral loads in patients with Crohn’s disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
- Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis